Table 2_Age-related trajectories of quality of life in community dwelling older adults: findings from the Survey of Health, Aging and Retirement in Europe (SHARE).docx by Sarah Mendorf (11632098)

“…Introduction<p>Previous longitudinal studies have identified numerous factors influencing quality of life (QoL) in people of older age (PoA). …”

Table 4_Human umbilical cord mesenchymal stem cells recover chemotherapy-induced premature ovarian failure.xlsx by Guojie Ji (21518650)

“…Differentially expressed genes (DEGs) were identified using RNA sequencing (RNA-seq), and their expression levels were validated through reverse transcription quantitative polymerase chain reaction (RT-qPCR).</p>Results<p>After hUC-MSCs therapy, the number of follicles recovered significantly and the atretic follicles decreased significantly. …”

Data Sheet 3_Age-related trajectories of quality of life in community dwelling older adults: findings from the Survey of Health, Aging and Retirement in Europe (SHARE).docx by Sarah Mendorf (11632098)

“…Introduction<p>Previous longitudinal studies have identified numerous factors influencing quality of life (QoL) in people of older age (PoA). …”

Table 1_Age-related trajectories of quality of life in community dwelling older adults: findings from the Survey of Health, Aging and Retirement in Europe (SHARE).docx by Sarah Mendorf (11632098)

“…Introduction<p>Previous longitudinal studies have identified numerous factors influencing quality of life (QoL) in people of older age (PoA). …”

Table 1_Human umbilical cord mesenchymal stem cells recover chemotherapy-induced premature ovarian failure.docx by Guojie Ji (21518650)

“…Differentially expressed genes (DEGs) were identified using RNA sequencing (RNA-seq), and their expression levels were validated through reverse transcription quantitative polymerase chain reaction (RT-qPCR).</p>Results<p>After hUC-MSCs therapy, the number of follicles recovered significantly and the atretic follicles decreased significantly. …”

Table 1_Next-generation sequencing of mitochondrial DNA reveals pathogenic variants and protective haplogroup D4 in esophageal cancer.xlsx by Xiucheng Jiang (18849564)

“…Notably, mitochondrial haplogroup D4 was significantly associated with a decreased risk of developing EC. …”

Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Conclusions<p>Patients with CTP B cirrhosis and T2DM receiving SGLT2i therapy experienced a significant improvement in renal, hepatic function, and glycemic control over 48 months compared to patients treated with insulin.…”

Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Conclusions<p>Patients with CTP B cirrhosis and T2DM receiving SGLT2i therapy experienced a significant improvement in renal, hepatic function, and glycemic control over 48 months compared to patients treated with insulin.…”

Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Conclusions<p>Patients with CTP B cirrhosis and T2DM receiving SGLT2i therapy experienced a significant improvement in renal, hepatic function, and glycemic control over 48 months compared to patients treated with insulin.…”

Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Conclusions<p>Patients with CTP B cirrhosis and T2DM receiving SGLT2i therapy experienced a significant improvement in renal, hepatic function, and glycemic control over 48 months compared to patients treated with insulin.…”

Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Conclusions<p>Patients with CTP B cirrhosis and T2DM receiving SGLT2i therapy experienced a significant improvement in renal, hepatic function, and glycemic control over 48 months compared to patients treated with insulin.…”

Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Conclusions<p>Patients with CTP B cirrhosis and T2DM receiving SGLT2i therapy experienced a significant improvement in renal, hepatic function, and glycemic control over 48 months compared to patients treated with insulin.…”

Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…</p>Conclusions<p>Patients with CTP B cirrhosis and T2DM receiving SGLT2i therapy experienced a significant improvement in renal, hepatic function, and glycemic control over 48 months compared to patients treated with insulin.…”

Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Conclusions<p>Patients with CTP B cirrhosis and T2DM receiving SGLT2i therapy experienced a significant improvement in renal, hepatic function, and glycemic control over 48 months compared to patients treated with insulin.…”

Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Conclusions<p>Patients with CTP B cirrhosis and T2DM receiving SGLT2i therapy experienced a significant improvement in renal, hepatic function, and glycemic control over 48 months compared to patients treated with insulin.…”

Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…</p>Conclusions<p>Patients with CTP B cirrhosis and T2DM receiving SGLT2i therapy experienced a significant improvement in renal, hepatic function, and glycemic control over 48 months compared to patients treated with insulin.…”

Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…</p>Conclusions<p>Patients with CTP B cirrhosis and T2DM receiving SGLT2i therapy experienced a significant improvement in renal, hepatic function, and glycemic control over 48 months compared to patients treated with insulin.…”

Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Conclusions<p>Patients with CTP B cirrhosis and T2DM receiving SGLT2i therapy experienced a significant improvement in renal, hepatic function, and glycemic control over 48 months compared to patients treated with insulin.…”

Data Sheet 1_Efficacy and mechanism of cyprosulfamide in alleviating the phytotoxicity of clomazone residue on maize seedling.docx by Lanlan Sun (1798921)

“…Additionally, the combination of CSA and Clo reduced MDA levels by 13.4%, increased SOD activity by 9.7% and GST activity by 26.7%, while elevating GSSG content by 31.3% compared to Clo alone, ultimately mitigating oxidative damage in maize plants. qRT-PCR analysis showed that the expression of five P450 genes (CYP72A5, CYP81A4, CYP81Q32, CYP81A9, CYP81A36), nine GST genes (GST30, GST31, GSTIV, GSTVI, GST21, GST7, GST37, GST25, IN2-1), and two UGT genes (UGT76C2, UGT83A1) significantly high increased by 6.74-, 10.27-, 4.98-, 10.56-, 25.67-, 16.70-, 46.92-,7.53-, 5.10-, 238.82-, 143.50-, 4.58-, 31.51-, 39.3-, 4.20-, 10.47-fold after CSA+Clo treatment compared to that in the Clo treatment. …”

Azole drugs have differential efficacy in varied models of immunosuppression in larval zebrafish hosts by Kevin E. Ayala (21979064)

“…<p>Fungal infections are an increasing cause of mortality in immunosuppressed human patients, and antifungal drug treatments are still ineffective in a significant percentage of cases. …”